CSL signs licensing deal with Eli Lilly for clazakizumab to treat kidney disease

Australia's CSL said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co , granting it certain rights to develop and commercialise clazakizumab, an antibody aimed a... ...